AUTHORS
John Lazar, MD PhD, Rebecca L Olin, MD2, Catherine Smith, MD3, Karin Gaensler, MD4, Peter Sayre, MD5, Timothy Ferng, MD6, Jerry Lee, MD, MPhil7, Lloyd E. Damon, MD8, Nicole Lei9, Aaron C. Logan, MD, PhD, MPhil10
AFFILIATIONS
1 University of California San Francisco, San Francisco, California, United States
2 University of California San Francisco, San Francisco, California, United States
3 University of California San Francisco, San Francisco, California, United States
4 University of California San Francisco, San Francisco, California, United States
5 University of California San Francisco, San Francisco, California, United States
6 University of California San Francisco, San Francisco, California, United States
7 University of California San Francisco, San Francisco, California, United States
8 University of California San Francisco, San Francisco, California, United States
9 University of California San Francisco, San Francisco, California, United States
10 University of California San Francisco, San Francisco, California, United States
ABSTRACT
Objective:
Next-generation sequencing based measurable residual disease (NGS-MRD) quantification has transformed the management of acute lymphoblastic leukemia (ALL). The clonoSEQ assay (Adaptive Biotechnologies) quantifies multiple immunoreceptor genes to a threshold of ≤1 leukemia-associated clonotype per million nucleated cells. The assay’s high sensitivity can complicate interpretation by detecting very low-level MRD of uncertain significance or discordant results among multiple clonotypes. We aimed to better understand the prevalence and clinical outcomes of low-level and/or discordant NGS-MRD to inform management of patients with ALL.
Study Design:
We performed a single-center retrospective cohort study of adult patients (age >18 at diagnosis) diagnosed with ALL who underwent MRD monitoring by between 2014 and 2026.
Results:
We identified 204 patients with a clonotype identification and ≥1 post-treatment MRD assessment. 185 patients were diagnosed with B-ALL (74% Ph-negative) and 19 with T-ALL. The median age at diagnosis was 32 years (range 19-83). Patients received a variety of therapies including pediatric-inspired regimens, hyperCVAD, and chemotherapy-free regimens.
Detection of multiple clonotypes was common: among B-ALL patients, 41% of patients had both IGH and IGK/L clonotypes, 46% had IGH alone, and 13% had IGK/L alone, while 65% of T-ALL patients had both TCRB and TCRG clonotypes, 3.5% had TCRB alone, and 31% had TCRG alone. For patients with multiple clonotypes, detection differed between clonotypes in 23% of MRD tests with multiple IG clonotypes (11% for TCR clonotypes). In B-ALL, the discordant positive clonotype was IGH in 31% of tests and IGK/L in 69%. The majority of discordant tests (73.4%) occurred with low-level clonotypes (<10 cells per million [CPM]), but discordance also occurred at higher MRD levels, with detected clones at 10–99 CPM in 7.4% and ≥100 CPM in 19.1% of discordant tests.
In ALL, early MRD assessment stratifies relapse risk. Among patients who achieved CR, those with NGS-MRD negativity in the first 150 days from diagnosis had highly favorable outcomes (2 year Kaplan-Meier estimated OS 98% and RFS 87% in our cohort) with poorer outcomes in patients who remained MRD positive (2 year estimated OS 86%/RFS 73%). Patients who maintained low-level MRD (IGH <1 CMP or IGK/L <10 CPM) in the initial 150 days of therapy had outcomes similar to patients who remained MRD positive at higher levels (2-yr OS 83%/RFS 71% for low/discordant MRD).
MRD monitoring is also critical throughout the course of treatment to capture impending relapse. In our cohort, patients received serial monitoring with a median of 6 MRD tests per patient (range 1 – 38). The testing periods covered a median 21 months (range 0.4 months – 142 months) with an average of 2.4 months between MRD tests (median 2.4, range 0.1 – 70 months). MRD progression after achieving MRD negativity occurred in 64 out of 166 (39%) patients. For patients with MRD progression, the median time between the first MRD negative test and subsequent MRD positivity was 217 days (range 15 – 1981) with 77% of events occurring in 1 year, 91% in 2 years, and 98% in 4 years.
Of patients with MRD progression, 55% developed only low-level (IgH <1 CPM or IgK/L <10 CPM) or discordant MRD. The outcomes of these patients were distinct from those with higher MRD values at MRD progression. In the high MRD group, morphologic relapse rates were high with a Kaplan-Meier estimated event rate at 2-years of 76%. In contrast, patients with low/discordant MRD had a low morphologic relapse rate (2-year estimated event rate of 14%). The 2-year incidence of relapse was higher when IGH was detectable ≥1 (40% if IGH only) than if only IGK/L was detectable (13% overall; 46% if >10 CPM). Correspondingly, OS differed between the two groups: estimated 2-year survival was 91% for patients with low/discordant MRD progression versus 62% for those with higher-level MRD (log-rank P < 0.01).
Conclusion:
In this study of discordant and low-level NGS-MRD in ALL, we demonstrate that the clinical significance of persistent MRD is context-dependent. During early treatment, persistent MRD — even if low level or discordant between clonotypes — correlates with inferior outcomes. On the other hand, development of low level or discordant MRD during maintenance or surveillance appears to be common and is associated with low rates of morphologic relapse and favorable outcomes.
DISCLOSURES
John Lazar, MD PhD: No relevant conflicts of interest to declare.